Innovation projects

Innovation projects

A collaborative project on brain cancer run by the IRB Barcelona and the Vall d’Hebron Institute of Oncology (VHIO) has received one of the funding concessions of the first call of the “Prova’t” programme, specific for Research Centres of Catalonia (CERCA) and funded by the “Generalitat de Catalunya” and ERDF resources.

Launched by the Botín Foundation, the “Mind the Gap” Technology Transfer Investment Programme supports the development of products and services that arise from lab bench results. IRB Barcelona has been awarded two “Mind the Gap” projects: “COLOSTAGE”, which is led by Drs. Eduard Batlle and Elena Sancho and aims to develop a diagnostic test for patients at risk of metastasis, and “NOSTRUM DRUG DISCOVERY”, a drug design platform headed by Dr. Modesto Orozco. The IRB Barcelona projects, two of the three chosen by the Foundation in 2012, will receive 500,000 euros each, as well as management, coordination and consulting support for two years.

BiomedTec is an IRB Barcelona internal programme supported by the Obra Social la Caixa and devoted to validate early-stage technologies from all disciplines. The development of the BiomedTec programme will foster the transfer of scientific results to the market, thus improving the quality of life of patients with cancer.

The first call was in 2012 and devoted to cancer. Due to the success of this first call, applications were broadened to all therapeutic areas. From the second call onwards it was officially denominated BiomedTec.

The Innovation Department is working to assure the continuation of the programme for the forecoming years.

IRB Innova 2015, the strategic plan for transfer activities at IRB Barcelona, has received funding for four years from the Ministry of Economy and Competiveness through the INNCIDE 2011 Programme. This programme aims to promote knowledge transfer through strengthening Technology Transfer Offices.

The Technology Transfer Programme run by the Botín Foundation offers research groups financial and management resources with the aim to ensure the dynamic and effective transfer of knowledge to society and the productive sector. Two IRB Barcelona researchers, namely Drs. Modesto Orozco and Joan Guinovart, were awarded this initiative in recent years. In 2013, Dr. Eduard Batlle’s group has been invited to join this prestigious programme.

IRB Barcelona Spin offs

Spin offs

Inbiomotion is a Barcelona-based personalized medicine company incorporated in 2011 with the goal of developing biomarkers that predict bone metastasis to improve the cancer patient’s quality of life.

Iproteos is a biotechnology company focused on the research and development of new therapeutic strategies based on peptidic protease inhibition. Iproteos is developing peptidic protease inhibitors for the treatment of CNS diseases.

Omnia Molecular (Omnia) designs and develops antiinfectives targeted at difficult-to-treat infections. Lead compounds are synthesized and optimized using a proprietary technology platform and are proven effective in several biological assays. Final proof of concept is conducted in animal infection models.


22 Sep 2014

Today the European Research Council (ERC) has announced the “Proof of Concept” awards for 50 European projects.

20 Sep 2014

Joan J.

9 Sep 2014

From 24 to 26 September, IRB Barcelona’s Innovation Office will move to Santiago de Compostela to participate in the Biospain Fair, the main biotech meeting in Southern Europe and 5th in the world

20 Jun 2014

IRB Barcelona is one of four institututions that, together with 22 companies, forms the Catalan delegation at the

Collaborations with Private Entities

Licensing Opportunities


Polyphenylprolines: novel drug delivery shuttles able to cross biological barriers (Ref. IRB_006)
This new identified family of drug delivery shuttles offers the possibility to carry a wide variety of small molecules as cargos, and to cross a range of biological barriers.




Cristina Horcajada
Head of Innovation
Tel: +34 93 40 31193